Beijing Kawin Technology Share-holding Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 12.53%

Beijing Kawin Technology Share-holding Co Ltd (688687) has an Asset Resilience Ratio of 12.53% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing Kawin Technology Share-holding C (688687) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥337.92 Million
≈ $49.45 Million USD Cash + Short-term Investments

Total Assets

CN¥2.70 Billion
≈ $394.79 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Beijing Kawin Technology Share-holding Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 688687 total assets.

Liquid Assets Composition Over Time

This chart breaks down Beijing Kawin Technology Share-holding Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Beijing Kawin Technology Share-holding C (688687) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥337.92 Million 12.53%
Total Liquid Assets CN¥337.92 Million 12.53%

Asset Resilience Insights

  • Moderate Liquidity: Beijing Kawin Technology Share-holding Co Ltd has 12.53% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Kawin Technology Share-holding Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Kawin Technology Share-holding Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for Beijing Kawin Technology Share-holding Co Ltd (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Kawin Technology Share-holding Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 10.29% CN¥287.50 Million
≈ $42.07 Million
CN¥2.79 Billion
≈ $408.72 Million
-3.12pp
2024-12-31 13.41% CN¥350.87 Million
≈ $51.34 Million
CN¥2.62 Billion
≈ $382.75 Million
-1.51pp
2023-12-31 14.92% CN¥365.33 Million
≈ $53.46 Million
CN¥2.45 Billion
≈ $358.25 Million
-8.21pp
2022-12-31 23.13% CN¥511.12 Million
≈ $74.79 Million
CN¥2.21 Billion
≈ $323.35 Million
+19.46pp
2021-12-31 3.67% CN¥80.00 Million
≈ $11.71 Million
CN¥2.18 Billion
≈ $318.67 Million
--
pp = percentage points

About Beijing Kawin Technology Share-holding Co Ltd

SHG:688687 China Biotechnology
Market Cap
$419.74 Million
CN¥2.87 Billion CNY
Market Cap Rank
#13201 Global
#3902 in China
Share Price
CN¥16.78
Change (1 day)
-2.10%
52-Week Range
CN¥15.01 - CN¥30.09
All Time High
CN¥40.56
About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more